国际标准期刊号: 2161-0460

阿尔茨海默病和帕金森病杂志

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • 打开 J 门
  • Genamics 期刊搜索
  • 学术钥匙
  • 期刊目录
  • 中国知网(CNKI)
  • 电子期刊图书馆
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • SWB 在线目录
  • 虚拟生物学图书馆 (vifabio)
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Parkinsons Disease Treatment Using Cell Transplantation

Sana Khalid

The testing of human fetus mesencephalic tissues with intrastriatal transplantation clinically,that are rich in dopamine producing neurons. Parkinson’s disease patient showed cell transplantation works and in many cases produces impervious improvements. Due to the poor availability of tissues, this method could only be administered in fewer number of patients and acclimitization was very difficult,leads to immense deflection in operative outcomes. For transplantation, undifferentiated (stem) cells and special (reprogrammed) cells could be availed potentially to emoulument dopamine producing neurons.From human embryonic stem cells dopamine producing neurons that will be of the appropriate substantia nigra phenotype can be emolumented in larger numbers and soon will be ready for application in patients.Dopamine producing neurons obtained from pluripotent stem cells of human are supposed to be used for clinical transplantation. In a controlled clinical studies,the present data justifies leading in a way with these dopamine producing neurons, that should be tested by choosing desirable patients, anticipation of cell and methods of transplantation.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。